Terungwa H. Iorkula, Osasere Jude-Kelly Osayawe, Daniel A. Odogwu, Latifat Oluwatobi Ganiyu, Emmanuel Faderin, Raymond Femi Awoyemi, Busayo Odunayo Akodu, Ikhazuagbe Hilary Ifijen, Omowunmi Rebecca Aworinde, Peter Agyemang and Odo Lovelyn Onyinyechi
RSC Adv., 2025,15, 3756-3828
From themed collection:
2025 Reviews in RSC Advances
Abstract
Pyrazolo[1,5-a]pyrimidines are a notable class of heterocyclic compounds with potent protein kinase inhibitor (PKI) activity, playing a critical role in targeted cancer therapy.
Abd-Allah S. El-Etrawy, Ahmad Ramadan, Farag F. Sherbiny, I. F. Zeid, A. A.-H. Abdel-Rahman and Mohamed A. Hawata
RSC Adv., 2024,14, 24671-24686
Abstract
A new series of amino acid derivatives linked to coumarin has been synthesized as CK2 inhibitors. Compound 7c outperforms doxorubicin in cell lines, while compound 5b shows superior CK2 inhibition compared to roscovetine.
Andreia Fortuna and Paulo J. Costa
Phys. Chem. Chem. Phys., 2026,28, 8832-8846
From themed collection:
Celebration of the 70th birthday of Prof. Giuseppe Resnati
Abstract
The impact of the halogen PB radii on protein-ligand binding energies using MM-PBSA was evaluated, with optimized radii for the usage of extra-points of charge (EPs) providing slightly better results.
Keiji Nishiwaki, Shiori Nakatani, Shinya Nakamura, Kenji Yoshioka, Eri Nakagawa, Masato Tsuyuguchi, Takayoshi Kinoshita and Isao Nakanishi
RSC Med. Chem., 2024,15, 1274-1282
Abstract
The design of the complex structure of CK2α and the inhibitor, leaving crystalline water molecules in the structure, significantly increased the inhibitory activity.
Nardin Wagih, Islam M. Abdel-Rahman, Nawal A. El-Koussi and Gamal El-Din A. Abuo-Rahma
RSC Adv., 2025,15, 966-1010
From themed collection:
2025 Reviews in RSC Advances
Abstract
Benzimidazoles as anticancer epigenetic factors.